Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tumoral and immune heterogeneity in an anti-PD-1-responsive glioblastoma: a case study.

Cold Spring Harbor molecular case studies - 1 Apr 2020

Restrepo Paula, Yong Raymund, Laface Ilaria, Tsankova Nadejda, Nael Kambiz, Akturk Guray, Sebra Robert, Gnjatic Sacha, Hormigo Adilia, Losic Bojan

Abstract excerpt

Clinical benefit of immune checkpoint blockade in glioblastoma (GBM) is rare, and we hypothesize that tumor clonal evolution and the immune microenvironment are key determinants of response. Here, we present a detailed molecular characterization of the intratumoral and immune heterogeneity in an IDH wild-type, MGMT-negative GBM patient who plausibly benefited from anti-PD-1 therapy with an unusually long 25-mo...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological
Share to Biological Variation, Population

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clonal Evolution

Share to Genetic Heterogeneity

Share to Glioblastoma

Share to Molecular Targeted Therapy

Share to Programmed Cell Death 1 Receptor

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 31907277
DOI: 10.1101/mcs.a004762
PMCID: PMC7133743

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tumoral and immune heterogeneity in an anti-PD-1-responsive glioblastoma: a case study.PMID 31907277Read ↗

Immunogenetics of glioblastoma: the future of personalized patient managementSemantic proximity Read ↗

Deep immune profiling reveals targetable mechanisms of immune evasion in checkpoint blockade-refractory glioblastomaSemantic proximity Read ↗

Heterogeneity of tumor-infiltrating lymphocytes ascribed to local immune status rather than neoantigens by multi-omics analysis of glioblastoma multiforme.Semantic proximity Read ↗

Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamicsSemantic proximity Read ↗

Multiomics and spatial mapping characterizes human CD8 + T cell states in cancerSemantic proximity Read ↗

Dual checkpoint blockade of glioblastoma with Anti-PD-1 and Anti-LAG-3 promotes expansion of tumor-reactive T cell clones along a unique pathway of differentiationSemantic proximity Read ↗

Intratumor Heterogeneity and Antitumor Immunity Shape One Another Bidirectionally.Semantic proximity Read ↗

Biological and therapeutic implications of multisector sequencing in newly diagnosed glioblastoma.Semantic proximity Read ↗

Single-cell transcriptomics reveals immunosuppressive microenvironment and highlights tumor-promoting macrophage cells in GlioblastomaSemantic proximity Read ↗

High tumor mutational burden and T-cell activation are associated with long-term response to anti-PD1 therapy in Lynch syndrome recurrent glioblastoma patient.Semantic proximity Read ↗

Single-cell transcriptomics reveals immunosuppressive microenvironment and highlights stumor-promoting macrophage cells in GlioblastomaSemantic proximity Read ↗

Transcriptional Plasticity and Platform-Specific Immune Targetability in IDH-Wildtype GlioblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.